NCT03562416View on ClinicalTrials.gov

Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects

PHASE2TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

July 5, 2019

Primary Completion Date

December 21, 2021

Study Completion Date

December 21, 2021

Conditions

Idiopathic Pulmonary FibrosisLung Transplant; Complications

Interventions

DRUG

Nintedanib

Nintedanib (BIBF 1120, Ofev)

DRUG

Placebo Oral Tablet

Placebo

Trial Locations (1)

19140

Temple University Hospital, Philadelphia

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Temple University

OTHER

NCT03562416 - Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects | Biotech Hunter | Biotech Hunter